NVCT logo

Nuvectis Pharma (NVCT)

Profile

Full Name

Nuvectis Pharma, Inc.

Ticker Symbol

NVCT

Exchange

NASDAQ

Country

United States

IPO

February 4, 2022

Indexes

Not included

Employees

13

Key Details

Price

$8.70(-8.71%)

Market cap

$203.51M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$1.11(+22.38% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Apr 2, 25 Maxim Group
Buy
Mar 17, 25 Laidlaw & Co.
Buy
Feb 25, 25 HC Wainwright & Co.
Buy
Aug 6, 24 HC Wainwright & Co.
Buy
May 8, 24 HC Wainwright & Co.
Buy
Sep 15, 23 HC Wainwright & Co.
Buy
Mar 7, 23 HC Wainwright & Co.
Buy
Feb 10, 23 HC Wainwright & Co.
Buy
Jul 13, 22 Ladenburg Thalmann
Buy
May 10, 22 HC Wainwright & Co.
Buy

Institutional Ownership

  • What is the ticker symbol for Nuvectis Pharma?
  • Does Nuvectis Pharma pay dividends?
  • What sector is Nuvectis Pharma in?
  • What industry is Nuvectis Pharma in?
  • What country is Nuvectis Pharma based in?
  • When did Nuvectis Pharma go public?
  • Is Nuvectis Pharma in the S&P 500?
  • Is Nuvectis Pharma in the NASDAQ 100?
  • Is Nuvectis Pharma in the Dow Jones?
  • When was Nuvectis Pharma's last earnings report?
  • When does Nuvectis Pharma report earnings?
  • Should I buy Nuvectis Pharma stock now?

What is the ticker symbol for Nuvectis Pharma?

The ticker symbol for Nuvectis Pharma is NASDAQ:NVCT

Does Nuvectis Pharma pay dividends?

No, Nuvectis Pharma does not pay dividends

What sector is Nuvectis Pharma in?

Nuvectis Pharma is in the Healthcare sector

What industry is Nuvectis Pharma in?

Nuvectis Pharma is in the Biotechnology industry

What country is Nuvectis Pharma based in?

Nuvectis Pharma is headquartered in United States

When did Nuvectis Pharma go public?

Nuvectis Pharma's initial public offering (IPO) was on February 4, 2022

Is Nuvectis Pharma in the S&P 500?

No, Nuvectis Pharma is not included in the S&P 500 index

Is Nuvectis Pharma in the NASDAQ 100?

No, Nuvectis Pharma is not included in the NASDAQ 100 index

Is Nuvectis Pharma in the Dow Jones?

No, Nuvectis Pharma is not included in the Dow Jones index

When was Nuvectis Pharma's last earnings report?

Nuvectis Pharma's most recent earnings report was on Nov 5, 2024

When does Nuvectis Pharma report earnings?

The next expected earnings date for Nuvectis Pharma is May 7, 2025

Should I buy Nuvectis Pharma stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page